Aligos Therapeutics (ALGS) announced the appointment of Kieron Wesson, PhD as Vice President, Head of Chemistry Manufacturing Controls, effective immediately. Prior to joining Aligos Therapeutics, Dr. Wesson served in positions of increasing responsibility, including as the Head of CMC and Supply Chain at Kezar Life Sciences and AN2 Therapeutics.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALGS:
- Aligos Therapeutics announces inducement grants under Nasdaq listing rule
- Aligos Therapeutics appoints Laura Kavanaugh as VP, head of legal
- Aligos Therapeutics presents data at EASL Congress 2025
- Aligos Therapeutics Reports Strong Q1 2025 Progress
- Aligos Therapeutics reports Q1 EPS ($2.11), consensus ($3.15)